Meningitis Vaccine Manufacturing: Fermentation Harvest Procedures Affect Purification - Careful analysis of an unusual precipitate identifies defects. - BioPharm International


Meningitis Vaccine Manufacturing: Fermentation Harvest Procedures Affect Purification
Careful analysis of an unusual precipitate identifies defects.

BioPharm International Supplements
Volume 24, Issue 4, pp. s21-s26

Figure 3: Damage to the harvest pump mating surfaces.
During early development, fatty acid characterization was part of the product impurity profile. Purified GCMP prior to conjugation contained <0.5% (w/w) fatty acids (palmitic, oleic, and 3-OH myristic). After the initial characterization, fatty acids were not routinely analyzed, although residual protein and nucleic acid levels were. These data confirmed that most fatty acids present were palmitic acid, the most prevalent fatty acid in Neisseria. Since the precipitate appeared in the 50K and 30K retentates, it was initially thought that there were flaws in the saponification and diafiltration steps. A significant portion of the root cause investigation examined the purification process, but nothing unusual about the deacetylation or saponification was uncovered. The in-process testing for residual protein and nucleic acid gave acceptable and typical results (see Table II). Since no protein or nucleic acids could be detected, and purification of GCMP was achieved, abnormalities in GCMP purification were ruled out as a root cause and the focus of the investigation shifted to the fermentation and harvest steps.

Table II: In-Process testing of 30K retentate for purity of the precipitation lots: residual protein and nucleic acid
Many of the fermentation inputs can affect cell metabolism and as a consequence, GCMP yield. Prior to the appearance of precipitation, the authors had seen increasing GCMP yields for several months. It was hypothesized that fermentation medium or operational parameters had changed, increasing GCMP yield in the form of lipidated-GCMP and therefore overwhelming the purification system. Several test runs were made to alter the fermentation process and reduce the GCMP yield, but had no apparent effect on the precipitation problem.

Figure 4: Fatty acid/GCMP % (w/w) in fermentation lots.
The GCMP harvest was more closely examined. This process involved circulating the contents of the fermentation vessel through 0.2 m hollow fiber cartridges using a circumferential piston pump. This pump is designed with moving part tolerances tighter than most similarly-sized rotary lobe pumps. Since the product is in the filter permeate, the fermentation medium is continuously circulated until the retained volume was low. We estimate that each cell passes through the harvest pump ~300 times. Upon examination, the harvest pump showed damage on mating surfaces in the lobes and rotor housing (see Figure 3). This damage had occurred when a catastrophic event scored these surfaces, rather than being the result of normal wear and tear. The pump continued to deliver expected volumes and pressures but the authors decided to replace it with an identical pump. The abnormal precipitation in the downstream process immediately ceased.

Table III: Concentration of palmitic acid entering the saponification step.
The authors concluded that the harvest pump, while operational, was damaged in such a way that it was also acting as a cell disruptor. Not only was more lipidated-GCMP sheared from the cell capsule, but the cell membranes were disrupted, forming fragments small enough to pass though the 0.2 m harvest filters (see Figure 2, steps 2 and 3), but large enough to be retained in the initial GCMP capture step (see Figure 2, step 4). Fatty acids in this material would be saponified in the deacetylation step (see Figure 2, step 5). If the sodium salts were soluble, they would be removed from the system during diafiltration. If they were not soluble, such as the sodium salt of palmitic acid, they would precipitate during this process. The ability of the damaged pump to mechanically extract fatty acids from the cells must have been increasing for several months before a critical point was reached where the amount or type entering the downstream process overwhelmed its ability to remove it.

blog comments powered by Disqus



GPhA Supports Restricted Access Bill
September 18, 2014
Baxter Initiates Voluntary Recall of Potassium Chloride Injection
September 17, 2014
European Commission Approves RoACTEMRA for Treatment of RA
September 9, 2014
PDA Announces Technical Report on Drug Shortages
September 9, 2014
Infinity and AbbVie Collaborate to Develop Oncology Drug
September 5, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here